Treatment effects of the multikinase inhibitor sorafenib on hepatoblastoma cell lines and xenografts in NMRI-Foxn1 nu mice

Liver International

Volumn 32, Issue 4, 2012, Pages 574-581

  Eicher, Carmen ^a   Dewerth, Alexander ^a   Kirchner, Bettina ^a   Warmann, Steven W ^a   Fuchs, Joerg ^a   Armeanu Ebinger, Sorin ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Apoptosis; Hepatoblastoma; Kinase inhibitor; Sorafenib; Tumour growth; Xenograft

Indexed keywords

ALPHA FETOPROTEIN; BAY 54 9085; MITOGEN ACTIVATED PROTEIN KINASE; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; SORAFENIB; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CELL VIABILITY; CONTROLLED STUDY; FEMALE; HEPATOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; TUMOR GROWTH; TUMOR VOLUME; XENOGRAFT;

ALPHA-FETOPROTEINS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZENESULFONATES; BLOTTING, WESTERN; CASPASE 3; CELL LINE, TUMOR; CELL SURVIVAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; FORKHEAD TRANSCRIPTION FACTORS; HEPATOBLASTOMA; IN SITU NICK-END LABELING; MICE; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN KINASE INHIBITORS; PYRIDINES; TETRAZOLIUM SALTS; THIAZOLES; TRANSPLANTATION, HETEROLOGOUS; TRANSPLANTS;

EID: 84858297002     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02729.x     Document Type: Article

References (25)

1. Zsiros J, Maibach R, Shafford E, et al. Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study. J Clin Oncol 2010; 28: 2584-90.
2. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-109.
3. Wilhelm SM, Adnane L, Newell P, et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008; 7: 3129-40.
4. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.
5. Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24: 4293-300.
6. Doi I. Establishment of a cell line and its clonal sublines from a patient with hepatoblastoma. Gann 1976; 67: 1-10.
7. Pietsch T, Fonatsch C, Albrecht S, et al. Characterization of the continuous cell line HepT1 derived from a human hepatoblastoma. Lab Invest 1996; 74: 809-18.
8. Warmann S, Gohring G, Teichmann B, et al. P-glycoprotein modulation improves in vitro chemosensitivity in malignant pediatric liver tumors. Anticancer Res 2003; 23: 4607-11.
9. Gollob JA, Wilhelm S, Carter C, Kelley SL. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol 2006; 33: 392-406.
10. Cairo S, Armengol C, De Reynies A, et al. Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer. Cancer Cell 2008; 14: 471-84.
11. Strumberg D, Clark JW, Awada A, et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 2007; 12: 426-37.
12. Perilongo G, Maibach R, Shafford E, et al. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med 2009; 361: 1662-70.
13. Von Schweinitz D, Hecker H, Harms D, et al. Complete resection before development of drug resistance is essential for survival from advanced hepatoblastoma-a report from the German Cooperative Pediatric Liver Tumor Study HB-89. J Pediatr Surg 1995; 30: 845-52.
14. Fuchs J, Rydzynski J, Von Schweinitz D, et al. Pretreatment prognostic factors and treatment results in children with hepatoblastoma: a report from the German Cooperative Pediatric Liver Tumor Study HB 94. Cancer 2002; 95: 172-82.
15. Ortega JA, Douglass EC, Feusner JH, et al. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: a report from the Children's Cancer Group and the Pediatric Oncology Group. J Clin Oncol 2000; 18: 2665-75.
16. Perilongo G, Shafford E, Plaschkes J. SIOPEL trials using preoperative chemotherapy in hepatoblastoma. Lancet Oncol 2000; 1: 94-100.
17. Sasaki F, Matsunaga T, Iwafuchi M, et al. Outcome of hepatoblastoma treated with the JPLT-1 (Japanese Study Group for Pediatric Liver Tumor) Protocol-1: A report from the Japanese Study Group for Pediatric Liver Tumor. J Pediatr Surg 2002; 37: 851-6.
18. Rossler J, Geoerger B, Taylor M, Vassal G. Small molecule tyrosine kinase inhibitors: potential role in pediatric malignant solid tumors. Curr Cancer Drug Targets 2008; 8: 76-85.
19. Morabito A, De Maio E, Di Maio M, Normanno N, Perrone F. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist 2006; 11: 753-64.
20. Warmann SW, Frank H, Heitmann H, et al. Bcl-2 gene silencing in pediatric epithelial liver tumors. J Surg Res 2008; 144: 43-8.
21. Karasarides M, Chiloeches A, Hayward R, et al. B-RAF is a therapeutic target in melanoma. Oncogene 2004; 23: 6292-8.
22. Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006; 66: 11851-8.
23. Yu C, Bruzek LM, Meng XW, et al. The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene 2005; 24: 6861-9.
24. Panka DJ, Wang W, Atkins MB, Mier JW. The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res 2006; 66: 1611-9.
25. Schmid I, Haberle B, Albert MH, et al. Sorafenib and cisplatin/doxorubicin (PLADO) in pediatric hepatocellular carcinoma. Pediatr Blood Cancer 2012; 58: 539-44.